State of Wyoming Makes New $632,000 Investment in Biogen Inc. $BIIB

State of Wyoming purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 2,923 shares of the biotechnology company’s stock, valued at approximately $632,000.

A number of other hedge funds also recently modified their holdings of BIIB. LSV Asset Management lifted its holdings in Biogen by 3.3% during the 4th quarter. LSV Asset Management now owns 316,815 shares of the biotechnology company’s stock worth $55,756,000 after buying an additional 9,976 shares during the period. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Biogen in the fourth quarter valued at about $2,006,000. Orbimed Advisors LLC acquired a new stake in shares of Biogen in the first quarter valued at about $11,293,000. Systematic Financial Management LP raised its position in shares of Biogen by 256.3% during the fourth quarter. Systematic Financial Management LP now owns 16,640 shares of the biotechnology company’s stock worth $2,928,000 after acquiring an additional 11,970 shares during the last quarter. Finally, Contrarius Group Holdings Ltd bought a new position in shares of Biogen during the fourth quarter worth about $11,431,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BIIB shares. Morgan Stanley increased their target price on shares of Biogen from $222.00 to $231.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Weiss Ratings lowered shares of Biogen from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday. Rothschild & Co Redburn increased their price objective on shares of Biogen from $180.00 to $190.00 in a research report on Thursday, April 30th. Finally, Piper Sandler reissued an “overweight” rating on shares of Biogen in a research note on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $227.07.

Biogen Price Performance

BIIB stock opened at $209.83 on Monday. The company has a market capitalization of $31.00 billion, a P/E ratio of 37.14, a price-to-earnings-growth ratio of 6.48 and a beta of 0.17. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. Biogen Inc. has a 52-week low of $131.52 and a 52-week high of $219.72. The business has a 50-day simple moving average of $203.76 and a two-hundred day simple moving average of $193.24.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.Biogen’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts expect that Biogen Inc. will post 12.5 EPS for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.